cART reduces HIV mother-to-child transmission, allowing vaginal delivery if viral load is low. cART is evolving and the optimal regimen for initiating treatment in pregnancy uncertain.
Routine clinical care data from nine London and Brighton sites, 2001 to 2015, were anonymised and collated. Demographics, baseline and subsequent HIV plasma loads, delivery information and ART were collected retrospectively. Essentially women started cART during this pregnancy and had HIV load re-measured after 14 days (+/-3 days). Elite controllers and women with an undetectable HIV load on day 14 (+/-3 days) were excluded. Time to undetectable was inferred from the mid-point between the last detected and first undetectable HIV loads. Data analysis was performed in SPSS.
160 women with median age 30 (range 17-42) years; 83% Black African/Caribbean, 12% white; HIV was acquired heterosexually in 96% and by IDU in 2%. Four had hepatitis virus co-infection. Baseline CD4 count and viral load were 313 (30–1136) cells/mL and 17290 (548–588020) cp/ml respectively. cART was commenced at 22 (5–39) weeks gestational age (GA). In the first 14 days of therapy, HIV half-life (T/2) was 2.5 (1.4–5.3) days and 105 (66%) achieved an undetectable HIV load at 36 weeks GA, 130 (81%) by delivery. Data were analysed by third agent: PI (n=114; 71%), NNRTI (n= 31; 18%) or Integrase Inhibitors (II) (n=7; 4%) giving HIV T/2 of 2.6; 2.3 and 1.5 days, whilst time to undetectable were 42, 41 and 27 days respectively. There were significant differences in T/2 by class (p = 0.001) and by individual agent (p = 0.02) but not for time to undetectable. T/2 was significantly slower for Atazanavir (ATZ) than for Nevirapine, Saquinavir and Lopinavir (Table). In logistic regression analysis ATZ (p 0.02) and GA at starting cART (p 0.03) were associated with HIV load at delivery. GA being 4 weeks later in those with a detectable HIV load at delivery whilst ATZ was associated with high suppression rate.
A range of cART combinations were effective in achieving undetectable HIV load at 36 weeks GA and at delivery. Correlation between initial decay and viral load at delivery was poor: ATZ had both a slower initial viral decay and a high rate of viral suppression. The limited data on II suggest they perform well in pregnancy and may be useful for high HIV load, especially if treatment is initiated after 20 weeks GA.